Which GLP-1 Is Right for Me? How Doctors Actually Decide

There is no single “best” GLP-1 for every person. The American Diabetes Association’s 2026 Standards of Care says the initial treatment approach for obesity should be individualized based on the person’s medical history, life circumstances, and preferences, and that combining approaches may be considered ^[1]. In practice, prescribers work through a series of filters: which FDA-approved indication you actually meet, whether an injection or a pill fits your routine, how much room there is to raise the dose, what side effects or conditions rule a drug out, what other medicines you take, and whether pregnancy is a possibility.

The choice also depends on what the treatment is for. In people with type 2 diabetes and overweight or obesity, the ADA says weight management should be a primary goal of treatment along with glycemic management ^[1]. Any magnitude of weight loss counts: a 5–7% loss of baseline weight improves glycemia and other intermediate cardiovascular risk factors, and a sustained loss of more than 10% usually confers greater benefits, including possible remission of type 2 diabetes ^[1].

What do the diabetes guidelines actually say about choosing?

The ADA’s recommendation 8.6 says to individualize the initial treatment approach — lifestyle and nutritional therapy, pharmacologic therapy, or metabolic surgery — based on medical history, life circumstances, and preferences, and to consider combining approaches ^[1]. Metabolic surgery, for reference, results in an average of more than 20% body weight loss ^[1]. Recommendation 8.6 frames the decision as a matching exercise between the person and the treatment, naming medical history, life circumstances, and preferences as the inputs.

The ADA also sets the monitoring frame. BMI should be screened annually, with overweight defined as BMI 25–29.9 kg/m² and obesity class 1, 2, and 3 defined as 30–34.9, 35–39.9, and 40 or above ^[1]. Where available, waist-to-hip ratio, dual-energy X-ray absorptiometry, or bioelectrical impedance analysis can be considered to confirm excess adiposity ^[1].

Which GLP-1 matches the indication you actually meet?

The first filter is the FDA-approved use, because each label covers a different set of patients.

Wegovy injection is approved, alongside a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight loss long term in adults and pediatric patients aged 12 and older with obesity, and in adults with overweight who have at least one weight-related comorbid condition ^[2]. It is also approved to reduce the risk of major adverse cardiovascular events — cardiovascular death, non-fatal heart attack, or non-fatal stroke — in adults with established cardiovascular disease and either obesity or overweight ^[2]. And it carries an accelerated approval for noncirrhotic MASH (formerly called NASH) with moderate to advanced liver fibrosis, stages F2 to F3, in adults; continued approval for that use may depend on verification of clinical benefit in a confirmatory trial ^[2].

Wegovy tablets are approved for adults only: cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight, and weight reduction in adults with obesity or overweight with at least one comorbidity ^[2].

Zepbound, a GIP and GLP-1 receptor agonist, is approved for weight reduction in adults with obesity or overweight with at least one weight-related comorbidity, and to treat moderate to severe obstructive sleep apnea in adults with obesity ^[3]. Foundayo tablets are approved for weight reduction in adults with obesity or adults with overweight with at least one weight-related comorbidity; the label lists Initial U.S. Approval: 2026 ^[4]. Saxenda is approved for adults and pediatric patients aged 12 and older with body weight greater than 60 kg and obesity, and for adults with overweight plus at least one comorbidity ^[5].

Rybelsus and Ozempic tablets are different: they are approved to improve glycemic control in adults with type 2 diabetes and to reduce major adverse cardiovascular events in adults with type 2 diabetes at high risk for those events — they carry no weight-management indication ^[6]. Mounjaro carries the same two diabetes indications, including glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes ^[7].

Every weight-management label states the drug is used in combination with a reduced-calorie diet and increased physical activity ^[2][3][4][5].

Injection or pill: what routine does each one demand?

Format is a major driver of the pick, because the routines are very different.

Wegovy injection is given once weekly on the same day each week, at any time of day, with or without meals, injected under the skin of the abdomen, thigh, or upper arm ^[2]. Zepbound is also a once-weekly subcutaneous injection ^[3]. Saxenda is a daily injection, once a day at any time, regardless of meals ^[5].

The oral semaglutide products — Wegovy tablets, Rybelsus, and Ozempic tablets — come with strict rules: take once daily on an empty stomach in the morning with water only, up to 4 ounces; swallow whole without splitting, crushing, or chewing; and wait at least 30 minutes before eating food, drinking other beverages, or taking other oral medicines ^[2][6].

Foundayo is taken once daily with or without food, swallowed whole, with no more than one tablet per day ^[4].

Product	Form	Frequency	Key label rules	Top dose on the label
Wegovy injection	Injection	Once weekly	Any time of day, with or without meals; abdomen, thigh, or upper arm [2]	Usual maintenance 2.4 mg once weekly [2]
Wegovy tablets	Pill	Once daily	Empty stomach, water only up to 4 oz, wait at least 30 minutes before food, drinks, or other oral medicines [2]	25 mg once daily [2]
Zepbound	Injection	Once weekly	Subcutaneous [3]	15 mg once weekly [3]
Foundayo	Pill	Once daily	With or without food, swallow whole, one tablet per day [4]	17.2 mg once daily [4]
Saxenda	Injection	Once daily	Any time of day, regardless of meals [5]	Recommended dose 3 mg daily [5]
Rybelsus / Ozempic tablets	Pill	Once daily	Empty stomach, water only up to 4 oz, wait at least 30 minutes [6]	May increase to 14 mg / 9 mg once daily if additional glycemic control is needed [6]

How much room is there to raise the dose?

Dose ceilings differ a lot, and that affects how much room a prescriber has if the first level is not enough.

Wegovy injection starts at 0.25 mg once weekly for 4 weeks and titrates every 4 weeks; the usual recommended maintenance dosage is 2.4 mg once weekly ^[2]. Strengths include a 7.2 mg/0.75 mL single-dose pen labeled WEGOVY HD ^[2]. Wegovy tablets start at 1.5 mg once daily for 30 days and titrate every 30 days to a maintenance dosage of 25 mg once daily, in strengths of 1.5, 4, 9, and 25 mg ^[2].

Zepbound starts at 2.5 mg once weekly for 4 weeks, then increases in 2.5 mg steps after at least 4 weeks; maintenance for weight reduction is 5, 10, or 15 mg once weekly, and for obstructive sleep apnea it is 10 or 15 mg once weekly, with a maximum of 15 mg once weekly ^[3]. The label says to consider treatment response and tolerability when selecting the maintenance dosage ^[3].

Foundayo titrates on a roughly monthly schedule: 0.8 mg once daily, then 2.5 mg after at least 30 days, then 5.5 mg after at least 30 more days, then optionally 9, 14.5, or 17.2 mg, with a maximum of 17.2 mg once daily ^[4]. Saxenda starts at 0.6 mg per day for one week and increases at weekly intervals to 3 mg daily; in pediatric patients, escalation may take up to 8 weeks, and those who do not tolerate 3 mg may have the dose reduced to 2.4 mg daily ^[5].

Rybelsus starts at 3 mg once daily for 30 days — a dose the label says is not effective for glycemic control — then 7 mg, then optionally 14 mg; Ozempic tablets follow the same pattern at 1.5 mg, 4 mg, and 9 mg ^[6]. Rybelsus and Ozempic tablets are not substitutable on a mg-to-mg basis ^[6].

What side effects and warnings rule certain drugs out?

Wegovy, Zepbound, Mounjaro, Saxenda, and Rybelsus/Ozempic tablets each carry a boxed warning about the risk of thyroid C-cell tumors. The semaglutide labels state that semaglutide causes these tumors in rodents ^[2][6]; the tirzepatide labels state that tirzepatide causes them in rats ^[3][7]; and the Saxenda label states that liraglutide causes them at clinically relevant exposures in both genders of rats and mice ^[5]. Each of these labels states that it is unknown whether the product causes thyroid C-cell tumors, including medullary thyroid carcinoma, in humans ^{[2][3][5][6][7]}. Foundayo’s boxed warning is worded differently: it states that orforglipron is not pharmacologically active in rats or mice and did not produce tumors in rodents, but that the human relevance of GLP-1 receptor-dependent thyroid C-cell tumors observed in rodents has not been determined ^[4].

All of these products are contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 ^{[2][3][4][5][6]}. Zepbound, Foundayo, and Rybelsus/Ozempic tablets are also contraindicated with known serious hypersensitivity to the drug or its excipients ^[3][4][6]; the Wegovy label lists known hypersensitivity to semaglutide or any excipient ^[2], and the Saxenda label lists hypersensitivity to liraglutide or any excipient ^[5].

The common side-effect lists overlap heavily. Zepbound’s most common reactions, reported in 5% or more of patients, include nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection site reactions, fatigue, hypersensitivity reactions, eructation, hair loss, and gastroesophageal reflux disease ^[3]. Foundayo’s most common reactions, reported in 5% or more of patients, are nausea, constipation, diarrhea, vomiting, dyspepsia, abdominal pain, headache, abdominal distension, fatigue, eructation, gastroesophageal reflux disease, flatulence, and hair loss ^[4]. Saxenda’s most common reactions, reported in 5% or more of patients, are nausea, diarrhea, constipation, vomiting, injection site reactions, headache, hypoglycemia, dyspepsia, fatigue, dizziness, abdominal pain, increased lipase, upper abdominal pain, pyrexia, and gastroenteritis; its label also advises monitoring heart rate at regular intervals ^[5].

Several conditions narrow the field. Zepbound, Foundayo, Saxenda, and Rybelsus/Ozempic tablets are not recommended in patients with severe gastroparesis ^[3][4][5][6]. Foundayo is not recommended in severe hepatic impairment ^[4]. Hypoglycemia risk rises when any of these is combined with insulin or an insulin secretagogue, and reducing the dose of those medicines may be necessary ^[3][4][5][6]. Pulmonary aspiration during general anesthesia or deep sedation has been reported with GLP-1 receptor agonists, so the labels instruct patients to tell providers about planned procedures ^[3][4][5].

How do the other medicines you take affect the choice?

Foundayo has the most interaction-specific rules. With a strong CYP3A4 inhibitor, its maximum dosage is 9 mg once daily, and strong CYP3A4 inhibitors that also inhibit OATP1B should be avoided; strong CYP3A4 inducers should be avoided, and with moderate inducers, effectiveness should be monitored and the dosage escalated as needed ^[4]. Foundayo also caps simvastatin at 20 mg once daily when used together ^[4].

Delayed gastric emptying from Zepbound, Foundayo, and Saxenda may affect the absorption of other oral medicines ^[3][4][5]. The oral semaglutide products add a timing rule: the 30-minute wait before taking any other oral medication ^[2][6].

What if you could become pregnant?

Zepbound’s label states it may cause fetal harm and should be discontinued when pregnancy is recognized; females using oral contraceptives are advised to switch to a non-oral method or add a barrier method for 4 weeks after starting and for 4 weeks after each dose escalation ^[3]. Foundayo carries the same fetal-harm warning and discontinuation advice, with a 30-day barrier or non-oral contraception window after initiation and after each dose escalation ^[4]. These contraception requirements are a practical factor in the choice for anyone who might become pregnant.

Can you take two GLP-1s at the same time?

No. Each label states that concomitant use with any other GLP-1 receptor agonist is not recommended — Wegovy with other semaglutide-containing products or any GLP-1 receptor agonist ^[2], Zepbound with other tirzepatide-containing products or any GLP-1 receptor agonist ^[3], Foundayo with another GLP-1 receptor agonist ^[4], and Saxenda with other liraglutide-containing products or any GLP-1 receptor agonist ^[5].

What monitoring happens after you start?

The ADA recommends monitoring obesity-related anthropometric measurements at least annually, and at least every 3 months during active weight management treatment ^[1]. For people with diabetes, the Wegovy label says to monitor blood glucose before starting and during treatment ^[2], and the Saxenda label says adults with type 2 diabetes should monitor blood glucose before starting and during treatment ^[5].

What questions are worth raising with the prescriber?

The ADA recommends person-centered, nonjudgmental language that fosters collaboration between the patient and clinician, and its individualization recommendation names life circumstances and preferences as inputs alongside medical history ^[1]. Questions that anchor to the labels include: which indication is being treated; what format and administration rules come with it; what the maximum dose is on that product; and how it interacts with current medicines ^{[2][3][4][5][6]}.

Sources

1. PubMed Central. Obesity and Weight Management for the Prevention and Treatment of Diabetes: Standards of Care in Diabetes–2026.
2. DailyMed. WEGOVY (semaglutide) injection, solution, and semaglutide tablet. Drug label.
3. Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, for subcutaneous use. Prescribing information. Initial U.S. approval: 2022.
4. DailyMed. FOUNDAYO (orforglipron) tablet, film coated. Drug label.
5. DailyMed. SAXENDA (liraglutide) injection, solution. Drug label.
6. DailyMed. OZEMPIC and RYBELSUS (oral semaglutide) tablet. Drug label.
7. DailyMed. MOUNJARO (tirzepatide) injection, solution, and MOUNJARO KWIKPEN. Drug label.
8. DailyMed. TRULICITY (dulaglutide) injection, solution. Drug label.
9. Business Group on Health. GLP-1 costs loom large for employers, forcing challenging coverage decisions, Business Group on Health survey finds.
10. DailyMed. OZEMPIC (semaglutide) injection, solution. Drug label.
11. US Food and Drug Administration. FDA approves first new molecular entity under national priority voucher program.